Farber doctor on cancer vaccine news

Key Points:

• Cancer vaccines are personalized therapies using mRNA technology to target the unique genetic makeup of a patient’s tumor, training T cells to recognize and remember cancer cells for long-term protection.
• Dr. Catherine Wu of Dana-Farber Cancer Institute led pioneering research in personalized cancer vaccines, demonstrating their effectiveness in melanoma patients nearly a decade ago, with long-term prevention of cancer recurrence.
• The NIH has launched a new initiative to advance cancer vaccine research, building on progress in melanoma and aiming to extend these therapies to harder-to-treat cancers like glioblastoma and ovarian cancer.
• Cancer vaccines are most effective when the disease burden is low, often used after initial treatment to prevent recurrence, but they may need to be combined with other therapies to combat metastatic cancers.
• The development of mRNA cancer vaccines predates COVID-19 vaccines, with the pandemic accelerating mRNA technology deployment; however, cancer vaccines face challenges due to tumor variability, making individualized approaches essential.